CERO

0.00377.50%
CB

Christopher B. Ehrlich

CEO & Chair

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Managing Director Senior Advisor of San Francisco of Locust Walk Partners, LLC from May 2026. Mr. Ehrlich serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serves as the Chief Executive Officer of Launch One Acquisition Corp. and serves its Director since July 2024. He was Independent Vice Chairman of CERo Therapeutics Holdings, Inc. since February 14, 2024 until September 30, 2024 and also served as its Interim Chief Executive Officer & Interim Chairman from September 30, 2024 until November 2024 and serves as its Chairman and Chief Executive Officer since October 1, 2024. He serves as Director of CERo Therapeutics Holdings, Inc. since February 14, 2024. He is also the Principal of Ehrlich Bioventures, LLC. He had been Managing Director at Locust Walk Partners, LLC since May 2013 and served as its Global Head of Biopharma. He served as the Chief Executive Officer and Director at Phoenix Biotech Acquisition Corp. from June 2021 to February 2024 and served as the Chief Executive Officer of PBAX from October 2021 until the Closing of the Business Combination in February 2024. Mr. Ehrlich served as Chief Executive Officer and Director at Locust Walk Acquisition Corp. since October 2020 to August 2021. Mr. Ehrlich joined InterWest Partners on August 1, 2000. He served as an Independent Director of eFFECTOR Therapeutics, Inc. since August 25, 2021 until June 21, 2024. He Co-Founded Anesiva, Inc. He served as the Director of Licensing and Business Development at Purdue Pharma L.P. He had been responsible for developing a biologic oncology franchise, including in licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue Pharma. He served as General Partner and Managing Director at Interwest Partners IX, L.P. InterWest Partners VIII, L.P. and InterWest Partners LLC. He worked in Business Development at Genentech, Inc.; in Venture Capital at The U.S. Russia Investment Fund and in Biotechnology Strategy Development at L.E.K. Consulting LLP. He was involved in founding AlgoRx Pharmaceuticals. He serves as a Director of Prostate Management Diagnostics Inc. since 2014. Mr. Ehrlich serves as a Director of BioMimetic Pharmaceuticals, Invuity and TransOral Pharmaceuticals Inc. Mr. Ehrlich served as a Director of Satori Pharmaceuticals Incorporated. He has been a Director of QuatRx Pharmaceuticals Company since October 2004 and Xenon Pharmaceuticals Inc. since January 2004. He served as Director of Follica, Inc. since August 2008. He served as Director of Carbylan Therapeutics, Inc. (Carbylan BioSurgery), Inc and CVRx, Inc. He was employed at Delta Private Equity Partners. He served as Director of Transcept Pharmaceuticals, Inc. since October 2005 until December 31, 2013. He is Member of Advisory Board of Dimension Inx Corp. from April 2023. He previously served as Senior Managing Director and the Global Head of Strategic Transactions at Locust Walk Partners from 2013 to 2021. He served as a Director of BioMimetic Therapeutics Inc. since October 2004 and Solace Pharmaceuticals, Inc. He served as a Director of KAI Pharmaceuticals, Inc. Avera Pharmaceuticals since May 2002. He serves as an Instructor and Advisor at the Center for Biotechnology at J.L. Kellogg Graduate School of Management since 2019. He served as a Board Observer of Applied Genetic Technologies Corporation. He sits on Advisory Boards for the Innovation and New Ventures Office at Northwestern University and the Peter Michael Foundation. Mr. Ehrlich holds an M.B.A. in Finance and Health Care from the J.L. Kellogg Graduate School of Management in 1998 and a B.A. (cum laude) in Government, from Dartmouth College in 1992.

Positions